Altre lingue GSK plc

Azioni

GSK

GB00BN7SWP63

Tempo reale stimato Cboe Europe Altri mercati azionari 15:16:04 23/04/2024			Variaz. 5gg	Var. 1 gen.
1.639 ^GBX	-0,02%		+1,89%	+13,16%

15:14	Edwards Lifesciences Corporation: la storia continua
22/04	I titoli azionari europei chiudono in rialzo nelle contrattazioni di lunedì; la Commissione Europea indaga su TikTok per possibili violazioni delle DSA	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Edwards Lifesciences Corporation : L’histoire se poursuit	10:36
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	22/04
GSK : Director/Pdmr Shareholding - Form 6-K	19/04
Studie: Brexit-Folgen verschärfen britische Arzneimittelknappheit	18/04
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	17/04
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	17/04
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	17/04
Met vallen en opstaan: waterstof	17/04
GSK : résultats cliniques positifs dans la gonorrhée	17/04
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	17/04
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	17/04
GSK : le virus contre le zona efficace pendant plus de 10 ans	17/04
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA \| GSK	17/04
GSK hails data on Shingles vaccine and gonorrhoea treatment	17/04
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	17/04
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	17/04
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	17/04
GSK : New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	17/04
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	17/04
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	16/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

GSK PLC : il 2023 si è chiuso con una nota forte; aumentata la guidance a medio-lungo termine

02 febbraio 2024 alle 15:40

Era meglio non invitarla: GSK

19 giugno 2023 alle 12:23